Skip to main content

Format:  Self-paced / asynchronous program
Engage with this recorded program on your schedule.

CE:  2 CEs total, read for more information on CEs
Fee: $35, read for more information on fees and scholarships

Program Description:

Participants will receive an introduction to psychedelic assisted psychotherapy, with a focus on ketamine, MDMA, and psilocybin. The talk will include reviewing the historical context of psychedelic work, an overview of research, future directions, and legal issues pertaining to the current state of psychedelic therapy. Information regarding supporting clients who are interested in therapeutic use of psychedelics will be discussed. Psychedelic-assisted therapy may be bringing a paradigm shift to treatment-resistant depression, substance use disorder, anxiety, and post-traumatic stress disorder; and the integration of these treatments raises ethical issues, which are further complicated by the regulatory and legal landscape. This workshop invites participants to slow down, be thoughtful, and proceed ethically. Dr. Tatyana Kholodokov will provide a grounding in current knowledge and research about these treatments; important historical context that includes lessons on cross-cultural practices and research omissions and abuses; and competencies and considerations for our role in supporting the healing of vulnerable populations.


Trainer: Tatyana Kholodkov, Ph.D. is a ketamine-assisted psychotherapist, licensed clinical psychologist, and owner and founder of Project Yes PLLC. Before working in private practice, she interned at the Durham VA and at Duke Integrative Medicine. She is a certified yoga instructor and much of her work involves enhancing the mind-body connection and cultivating presence. Dr. Kholodkov merges her training background in clinical psychology with nearly a lifetime studying eastern philosophy, yoga, and meditation.


Learning Objectives:

At the conclusion of this program, participants will be able to:

  1. Name 4 types of psychedelics and at least 1 indication and contraindication for psychedelic-assisted therapy in the treatment of various mental health conditions, such as depression, anxiety, addiction, and PTSD.
  2. List and describe at least 3 ethical considerations involved in the use of psychedelic substances in therapy
  3. Describe at least 1 potential future direction of psychedelic-assisted therapy research and clinical practice.


Argento, E., Goldenberg, S., Deering, K., Lavalley, J., Braschel, M., Bingham, B., & Shannon, K. (2022). Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada. Drug and Alcohol Dependence Reports, 3, 100044-100044.

Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022). Psychedelic-assisted psychotherapy: A systematic review of associated psychological interventions. Frontiers in Psychology, 13, 887255-887255.

Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J., Ritvo, P., Mattina, G., Bhat, V., Diep, C., & Ladha, K. S. (2022). Ketamine assisted psychotherapy: A systematic narrative review of the literature. Journal of Pain Research, 15, 1691-1706.

George, D. R., Hanson, R., Wilkinson, D., & Garcia-Romeu, A. (2022). Ancient roots of Today’s emerging renaissance in psychedelic medicine. Culture, Medicine and Psychiatry, 46(4), 890-903.

Goldpaugh, D. D. (2022). Finding the divine within: Exploring the role of the sacred in psychedelic integration therapy for sexual trauma and dysfunction. Sexual and Relationship Therapy, 37(3), 314-323.

Haeny, A. H., Lopez, J., Grigas, P. C., Crouch, M., Davis, A. K., & Williams, M. (2023). Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and CanadaJournal of Substance Use and Addiction Treatment, 149, 209035.

Hutchison, C., & Bressi, S. (2021). Social work and psychedelic-assisted therapies: Practice considerations for breakthrough treatments. Clinical Social Work Journal, 49(3), 356-367.

Pilecki, B., Luoma, J. B., Bathje, G. J., Rhea, J., & Narloch, V. F. (2021). Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduction Journal, 18(1), 40-40.

Strauss, D., de la Salle, S., Sloshower, J., & Williams, M. T. (2022). Research abuses against people of colour and other vulnerable groups in early psychedelic researchJournal of Medical Ethics, 48(10), 728-737.

Wallace, B., & Rea, K. (2021). Enhancing equity-oriented care in psychedelic medicine: Utilizing the EQUIP framework. The International Journal of Drug Policy, 98, 103429.

Yeung, A., Sapirstein, G., Crain, L. D., Cramer, M. A., & Forcen, F. E. (2023). Pharmacotherapy and ketamine assisted psychotherapy for treatment-resistant depression: A patient with lifelong self-doubt and self-criticism. The Journal of Clinical Psychiatry, 84(3)


UNC Chapel Hill – Clinical Lecture Series Programs


Comments are closed.